Investigational Drug Lorundrostat Reduces Blood Pressure and Kidney Damage Marker in CKD Patients with Hypertension

A recent study has demonstrated that lorundrostat, an investigational medication, significantly reduces blood pressure and the urine albumin-to-creatinine ratio in patients diagnosed with chronic kidney disease (CKD) and hypertension. These findings suggest potential clinical benefits for individuals managing these coexisting conditions.

The research highlights that lorundrostat effectively lowered both systolic and diastolic blood pressure levels in the study participants. Additionally, the treatment was associated with a reduction in the urine albumin-to-creatinine ratio, a key marker of kidney damage often elevated in CKD patients. The results provide new insights into the drug’s impact on two critical health indicators for this patient population. Further details about the study design or participant demographics were not disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 23, 2025

Related posts:

CDMO Partnerships: Clear Communication and IP Protection Are Key Considerations in Complex Contracts Studies Find Portfolio Diet Linked to Lower Cardiovascular Disease Risk and Mortality Rates FDA Authorizes Expanded Access for ImmunityBio’s Anktiva to Treat Lymphopenia Santosh Mahil Appointed CEO of Sekhmet Pharmaventures Backed by PAG, CX Partners, and Samara Capital

Author

Mark Chiang